Title
Transcriptomics and solid tumors: The next frontier in precision cancer medicine.

Permalink
https://escholarship.org/uc/item/3bj9b3nc

Authors
Tsimberidou, Apostolia M
Fountzilas, Elena
Bleris, Leonidas
et al.

Publication Date
2020-09-17

DOI
10.1016/j.semcancer.2020.09.007

Peer reviewed
Transcriptomics and Solid Tumors: The Next Frontier in Precision Cancer Medicine

Apostolia M. Tsimberidou, MD, PhD\textsuperscript{a}, Elena Fountzilas, MD, PhD\textsuperscript{b}, Leonidas Bleris\textsuperscript{c}, Razelle Kurzrock, MD\textsuperscript{d}

\textsuperscript{a}The University of Texas MD Anderson Cancer Center, Department of Investigational Cancer Therapeutics, Houston, TX, USA

\textsuperscript{b}Department of Medical Oncology, Euromedica General Clinic, Thessaloniki, Greece

\textsuperscript{c}Bioengineering Department, The University of Texas at Dallas, Richardson, TX, USA

\textsuperscript{d}Center for Personalized Cancer Therapy and Division of Hematology and Oncology, UC San Diego Moores Cancer Center, San Diego, CA, USA

Corresponding author: Apostolia-Maria Tsimberidou, MD, PhD, Professor, Department of Investigational Cancer Therapeutics, The University of Texas MD Anderson Cancer Center, 1515 Holcombe Boulevard, Unit 455, Houston, TX 77030, Phone: 713-792-4259, Fax: 713-794-3249, Email: atsimber@mdanderson.org
Abstract

Transcriptomics, which encompasses assessments of alternative splicing and alternative polyadenylation, identification of fusion transcripts, explorations of noncoding RNAs, transcript annotation, and discovery of novel transcripts, is a valuable tool for understanding cancer mechanisms and identifying biomarkers. Recent advances in high-throughput technologies have enabled large-scale gene expression profiling. Importantly, RNA expression profiling of tumor tissue has been successfully used to determine clinically actionable molecular alterations. The WINTHER precision medicine clinical trial was the first prospective trial in diverse solid malignancies that assessed both genomics and transcriptomics to match treatments to specific molecular alterations. The use of transcriptome analysis in WINTHER and other trials increased the number of targetable -omic changes compared to genomic profiling alone. Other applications of transcriptomics involve the evaluation of tumor and circulating noncoding RNAs as predictive and prognostic biomarkers, the improvement of risk stratification by the use of prognostic and predictive multigene assays, the identification of fusion transcripts that drive tumors, and an improved understanding of the impact of DNA changes as some genomic alterations are silenced at the RNA level. Finally, RNA sequencing and gene expression analysis have been incorporated into clinical trials to identify markers predicting response to immunotherapy. Many issues regarding the complexity of the analysis, its reproducibility and variability, and the interpretation of the results still need to be addressed.
The integration of transcriptomics with genomics, proteomics, epigenetics, and tumor immune profiling will improve biomarker discovery and our understanding of disease mechanisms and, thereby, accelerate the implementation of precision oncology.

**Keywords:** gene expression, precision oncology, noncoding RNA, RNA sequencing transcriptomics

**Abbreviations**
cDNA: complementary DNA
CNV: copy-number variation
CUP: cancer of unknown primary
EGOG: Eastern Cooperative Oncology Group
GTEx: Genotype-Tissue Expression
INFORM: Individualized Therapy for Relapsed Malignancies in Childhood
mRNA: messenger RNA
NGS: next-generation sequencing
PIPseq: Precision in Pediatric Sequencing
RNAi: RNA interference
RNA-seq: RNA sequencing
rRNA: ribosomal RNA
RT-qPCR: reverse transcriptase quantitative polymerase chain reaction
siRNA: short interfering RNA
tRNA: transfer RNA
WIN: Worldwide Innovative Network
**Background**

Recent advances in technology have improved our understanding of carcinogenesis and led to the discovery of novel therapeutic targets. Precision oncology combines data from tumor genomic profiling, cell-free DNA assays, proteomic and immune profile analyses, and assessments of other markers to individualize treatment according to unique patient and tumor characteristics.\(^1,2\) Artificial intelligence and innovative clinical trial designs, including adaptive and N-of-1 trials, hold promise to accelerate the collection, analysis, and application of data on predictive biomarkers and novel targeted agents.\(^3,4\) Until recently, precision oncology focused mainly on genomic profiling of tumors.\(^5,6\) Advances in next-generation sequencing (NGS) technologies have enabled the time- and cost-efficient incorporation of genomics into daily clinical practice. Several precision oncology trials have demonstrated the clinical significance of genomics in identifying molecular alterations that are successfully targeted by novel treatments.\(^3,4,6-9\) Comprehensive gene panels are currently being used to identify molecular therapeutic targets and prognostic and predictive biomarkers and prospective clinical trials are assessing the value of molecular testing in treatment selection across various tumor types.\(^10-19\)

Despite this significant progress in the implementation of precision oncology, several challenges need to be addressed in clinical research and practice. First, it is critical to enhance our knowledge of tumor biology, the mechanisms of carcinogenesis, and driver alterations to improve our ability
to identify robust prognostic and predictive biomarkers. Additionally, to date, only a few molecular alterations have been successfully targeted by novel agents. Many of these alterations are rare, and a large number of patients need to be screened to identify a single potential therapeutic target. Indeed, the proportion of patients who are matched to therapy in precision oncology trials generally ranges from 5% to 50% and often depends on whether the study is conducted in a specialized clinic with access to novel agents, off-label drug use, timely molecular profiling, and the expertise of clinical trial leaders in genomics. Therefore, our understanding of cancer complexity dictates that additional precision oncology methodologies need to be incorporated to enhance patient-treatment matching and prevent the development of treatment resistance.

Transcriptomic analyses have been included in precision oncology trials only recently and infrequently (Table 1). Transcriptomics refers to the study of all the RNA transcripts in a cell population, typically by using high-throughput technologies, namely microarrays and RNA sequencing (RNA-seq). In contrast to analysis of DNA sequencing data, the assessment of RNA status and measurement of transcripts can correlate gene expression with biologic activity and cellular status (Table 2). Gene expression, in turn, is influenced by genetic and epigenetic factors, such as DNA methylation and histone modifications. Early results of clinical trials suggest that transcriptomic analysis can increase the number of patients matched to drugs. Therefore, transcriptomics is a potentially valuable, though
underused, technique for unraveling the underlying mechanisms of cancer and moving towards the implementation of precision oncology.
**History**

Early methods to assess gene expression included Northern blotting, reverse transcriptase quantitative polymerase chain reaction (RT-qPCR), and sequencing of short nucleotide arrays (expressed sequence tags) that were generated from complementary DNAs (cDNAs). However, these methods were developed to evaluate limited numbers of transcripts and are inadequate for comprehensive RNA profiling. Subsequently, serial analysis of gene expression\(^{65}\) and DNA microarrays enabled the analysis of large-scale gene expression arrays.\(^{57,66-68}\) With microarrays, investigators can quickly assess the expression levels of thousands of genes simultaneously. Comprehensive profiling of tumor samples, normal tissues, and cancer cell lines yielded a large volume of transcriptomic data. Dedicated databases were developed to store gene expression datasets that were made publicly available to allow their use by other investigators.\(^{69,70}\) Examples of the implementation of gene expression analysis in clinical practice include the commercially available MammaPrint and Oncotype DX assays, which are used to assess prognosis and/or select treatment in patients with breast cancer.\(^{51,71-}\)

**Transcriptome biology**

*Dynamic nature of the transcriptome*
In multicellular organisms, the same genes, and thus the same genome, are found in almost every cell. Not every gene is transcriptionally active in every cell, however, and different patterns of gene expression appear in different types of cells. In addition, multiple RNA variants can be produced by a single gene owing to alternative splicing, RNA editing, or alternative transcription initiation and termination sites. The total transcriptional activity, that is, the full range of RNA molecules expressed, is reflected in the transcriptome of an organism. The transcriptome can be represented as the percentage of the genetic code that is transcribed into RNA molecules, which is estimated to be less than 5% of the genome in humans.\textsuperscript{72} In contrast to the genome, the transcriptome changes in response to cellular cues. Indeed, an organism's transcriptome varies dynamically depending on many factors, including environmental conditions and developmental stage.

\textit{Epitranscriptomics}

Epitranscriptomics, also known as RNA epigenetics, describes the diverse posttranscriptional modifications occurring in cellular RNA. This dynamic processing occurs during RNA maturation under the regulation of RNA-binding proteins. To date, more than 150 types of RNA modifications have been identified, including RNA methylation and editing.\textsuperscript{73} While the exact role of these modifications is still under investigation, studies have shown that it extends from maintaining the structure of RNA to regulating
critical cell systems and that disruptions in RNA processing are associated with various diseases, including cancer.\textsuperscript{74,75} Research focusing on specific modifications has revealed associations between deregulation of RNA processing and cancer progression, aggressive tumor behavior, and deregulated cellular processes.\textsuperscript{76,77} Given the oncogenic nature of these modifications, their regulators could be targeted for novel therapies.

**Functional uses of transcriptomics**

*Identification of therapeutic targets*

Transcriptomic data have been incorporated into many different tumor molecular profiles to increase the number of targetable molecular alterations and provide additional therapeutic options to patients with advanced cancer.\textsuperscript{7,32-34,78,79} In one study, gene expression profiling of longitudinally collected primary breast tumors and metastatic lesions identified several highly targetable genes.\textsuperscript{78} Administration of therapeutic agents against these alterations in patient-derived xenograft models led to a statistically significant antitumor response vs. controls. In another study of 1049 children and young adults with *de novo* acute megakaryocytic leukemia, RNA-seq revealed druggable targets.\textsuperscript{79} Importantly, in our WINTHER precision medicine clinical trial, which prospectively assessed both genomics and transcriptomics in diverse solid malignancies, the use of transcriptomic analysis increased the number of targetable -omic changes by a third over NGS.\textsuperscript{7}
Detection of gene fusions

Conventional cytogenetic analyses, including fluorescence in situ hybridization and RT-qPCR, have been widely used for fusion gene detection. However, these methods are designed to discern the presence of specific known gene fusions, not identify novel ones. Newer techniques and algorithms have been developed for the performance of wide-scale RNA-seq to detect novel gene fusions.\textsuperscript{38-40}

MicroRNA sequencing

Transcription is the process by which individual genes are copied into RNA molecules to build the transcriptome. The translation of these RNA molecules into proteins constructs the proteome. The RNA content of a cell includes coding and noncoding RNA. The coding RNA, which makes up the transcriptome, consists of messenger RNAs (mRNAs). The noncoding RNAs primarily include ribosomal RNAs (rRNAs), which are components of ribosomes (the structures on which protein synthesis takes place), and transfer RNAs (tRNAs), which are small molecules that are involved in protein synthesis by carrying amino acids to the ribosome and ensuring that they are linked together in the order specified by the nucleotide sequence of the mRNA that is being translated into a protein. In addition to rRNAs and tRNAs, short regulatory non-coding RNAs, including piwi-associated RNAs, endogenous short-interfering RNAs, and microRNAs (Figure 1), have
received significant attention due to their role as regulators of gene expression.

*Regulation by microRNAs*

Over the past decade, several studies have focused on revealing the microRNA (miRNA) repertoire. These small non-protein-coding RNA molecules (18-25 nucleotides) are capable of controlling gene expression by binding to mRNA targets, thus interfering in the final protein output. MiRNAs have been recognized as major regulators of biological features including proliferation, migration, and apoptosis. MiRNA profiling has been successfully used to molecularly classify tumors, to assess the prognosis of patients with different tumor types, and to predict the development of resistance to treatments. MiRNAs and miRNA mimics are currently being evaluated in clinical trials as therapeutic agents (NCT02369198, NCT01829971, NCT02580552). Intriguing data have emerged from the study of circulating miRNAs. Studies show that miRNAs, encapsulated in exosomes, are released from cells and can be detected in biological fluids. The noninvasive assessment of circulating miRNAs is an appealing approach for disease monitoring and diagnosis. Several studies are investigating the role of circulating miRNAs as cancer diagnostic and prognostic biomarkers.

*Noncoding RNA sequencing*

In addition to miRNAs, gene expression profiling can reveal other molecular elements, including other noncoding RNAs. Noncoding RNAs are
transcribed from non-protein-coding regions of the genome and have a wide range of regulatory functions.\textsuperscript{99,100} Depending on their transcript size, they are categorized as small (< 200 bp) or long noncoding RNAs (IncRNAs; > 200 bp, up to \(\sim 100\) kb). Noncoding RNAs have been shown to play an important role in cancer, and noncoding RNA expression profiling has diagnostic, prognostic, and predictive value in patients with solid and hematologic malignancies.\textsuperscript{36,101} Recent studies show that circulating noncoding RNA levels in body fluids (eg, serum, urine) differ between individuals with and without cancer.\textsuperscript{101-104} These data suggest that noncoding RNAs could be used as diagnostic biomarkers in cancer screening. Other investigators have shown that profiling of noncoding RNAs has prognostic utility in patients with cancer.\textsuperscript{36,101} Finally, studies are currently evaluating the role of circulating noncoding RNAs in predicting response or resistance to various treatments. Preliminary data suggest that this approach might provide useful insights with which to identify patients who are likely to have a response to therapy.\textsuperscript{105-108} The clinical appeal of the use of noncoding RNAs and miRNAs as biomarkers is that they can be obtained noninvasively via liquid biopsies. However, the clinical utility of these approaches has yet to be prospectively defined and validated.

\textit{Prognostic gene expression signatures}

Several studies have evaluated the presence of prognostic biomarkers through transcriptomic analysis. Gene expression signatures are alterations in the expression of single genes or sets of genes with a validated
association with disease prognosis, therapeutic benefit, or cancer diagnosis. Despite recent technological advances, robust molecular prognostic biomarkers are still lacking in clinical practice. As a result, there is a great need to improve risk assessment in patients with cancer in order to identify patients at high risk of recurrence or death. When identified, these patients might be treated more aggressively or with different therapeutic strategies.

To improve risk stratification, prognostic multigene assays have been developed and validated in lung,\textsuperscript{109} breast,\textsuperscript{51,57,110} colon,\textsuperscript{111,112} and other tumor types.\textsuperscript{113-117} These gene expression signatures provide prognostic information independently of clinicopathologic features and have been shown to improve the stratification of patients based on risk of recurrence. However, only a few, such as Oncotype DX in breast cancer, are recommended in international patient management guidelines for use in clinical practice to predict whether a patient is likely to have a recurrence of the disease.\textsuperscript{71} Future studies might reveal the prognostic value of additional gene expression signatures in different tumor types.

\textit{Predictive gene expression signatures}

Other studies have employed transcriptome analysis to identify gene expression signatures that can predict response to specific cancer therapies.\textsuperscript{118,119} However, only a small number of predictive signatures have been validated in prospective randomized clinical trials. Therefore, only a few gene expression signatures with verified clinical validity are used in daily
practice. For instance, the validated predictive models Oncotype DX is often used in patients with hormone-receptor–positive, human epidermal growth factor receptor type 2–negative, early-stage breast cancer to predict benefit from adjuvant chemotherapy.\textsuperscript{71} It is critical that these signatures are robust, highly reproducible, and validated in diverse populations beyond the tightly controlled environment of clinical trials.

\textit{Classification of cancer of unknown primary}

Transcriptomics holds promise as an additional tool for the accurate classification of cancer of unknown primary (CUP). Several investigators have explored gene expression profiles and revealed biomarkers indicative of the origin of the tumor in patients with CUP.\textsuperscript{52-56,120} In one study, transcriptome analysis of 16 674 tumors corresponding to 22 tumor types revealed a 154-gene expression signature that aided the identification of tumor origin.\textsuperscript{120} Independent validation of the signature was successfully performed using 9626 primary tumors. In another study, a cancer type classifier was developed using gene expression data from more than 10 000 tissue samples from 30 tumor types.\textsuperscript{56} The accuracy of the classifier was high (77\%-88\%) and varied according to the primary tumor type, the purity of the tumor sample, and the site of tumor tissue (primary or metastatic). Finally, computational algorithms have been employed to mine RNA expression datasets and identify diagnostic classifiers.\textsuperscript{55} Gene expression profiling can be incorporated into diagnostic algorithms for patients with CUP to increase rates of accurate classification and improve understanding of patients’
prognoses. However, in randomized trials, treating CUP according to tissue-of-origin signatures did not effectively improve outcomes.\textsuperscript{121,122}

Assessment of tumor heterogeneity

Investigators exploring the intratumor heterogeneity of renal tumors (primary and corresponding metastatic sites) demonstrated that tumors are not only genomically but also transcriptomically heterogeneous.\textsuperscript{123} Specifically, they showed that gene expression signatures suggestive of good and poor prognoses can be identified within the same tumor. Others explored tumor heterogeneity between foci of multifocal or multicentric invasive lobular breast carcinoma and observed heterogenous transcriptional profiles in expression analysis of 730 genes.\textsuperscript{124} More recently, studies have incorporated single-cell RNA-seq methods to explore tumor heterogeneity in detail.\textsuperscript{59,125-127}

Prediction of response to immuno-oncology

Despite unprecedented improvement in patient outcomes by the use of immune checkpoint inhibitors, mechanisms of resistance significantly limit the benefit from these treatments. Several genomic alterations are being evaluated as predictive biomarkers for immunotherapy.\textsuperscript{128-132}

In recent studies, RNA-seq and gene expression analysis have been incorporated to predict responsiveness to immunotherapy. In 1 study, analysis of the genome and transcriptome of melanoma tissue samples identified biomarkers that predicted response to anti-PD-1 therapy.\textsuperscript{133}
addition, transcriptomic profiles suggested that innate tumor resistance to anti-PD-1 immunotherapy was associated with mesenchymal and inflammatory tumor phenotypes. In a study of metastatic melanoma tumors, gene expression profiling showed that tumors with PTEN loss had lower expression of inflammation-related genes, suggesting that PTEN loss could be associated with resistance to immunotherapy. Other studies identified gene expression profiles associated with response or resistance to immunotherapeutic agents. Transcriptome analysis has also been used to study how the tumor microenvironment evolves after treatment with immunotherapy, as well as tumor immune heterogeneity and tumor immune classification.

Transcriptomic silencing

Gene expression silencing is a mechanism of transcriptional regulation in mammalian cells. It is mediated by RNA interference (RNAi), in which a small noncoding RNA associates with RNA-induced silencing complex and degrades target mRNAs. Gene silencing is seen with exogenous (e.g., viral, bacterial) and endogenous (e.g., transgene, transposon) sequences. In addition, RNAi is involved in the regulation of gene expression and other biologic processes. Transcriptomic silencing is used in combination with gene expression profiling to identify novel biomarkers and therapeutic targets. For instance, in 1 study of 9873 prostate tissue samples, gene expression profiling revealed 295 genes that had high mRNA expression in prostate cancer samples. An RNAi-based cell viability assay was incorporated to
demonstrate the role of gene silencing in prostate cancer cell lines and silencing of a candidate gene (*ERGIC1*) led to inhibition of ERG mRNA expression and decreased proliferation of ERG-positive prostate cancer cells.\textsuperscript{140} These data suggested that ERG could be tested as a candidate drug target.

RNAi-mediated gene silencing is an appealing approach for use in cancer treatment because it can silence oncogenes and other driver genes involved in cancer cell proliferation, the cell cycle, and tumor progression. In this vein, clinical trials are currently evaluating the clinical benefit from the use of short interfering RNA (siRNA)-based treatments in patients with cancer. PROTACT is a phase II trial assessing the clinical utility of siG12D LODER in combination with chemotherapy in patients with locally advanced pancreatic cancer (NCT01676259). In this study, SiG12D LODER, a miniature biodegradable polymeric matrix that encloses siRNAs targeting G12D-mutated *KRAS*, is implanted in the tumor via endoscopic ultrasound. Published data from another phase I/IIa trial evaluating the administration of SiG12D LODER as first-line treatment (in combination with chemotherapy) in 15 patients with locally advanced pancreatic cancer showed that this therapeutic approach was safe and well tolerated.\textsuperscript{141} Another phase I trial is evaluating the administration of a liposomal agent consisting of siRNAs against EphA2 that are encapsulated into 1,2-dioleoyl-sn-glycerol-3-phosphatidylcholine liposomes in patients with advanced cancer (NCT01591356). Both trials are currently recruiting patients.
In addition, RNA-seq, along with NGS, has revealed transcriptomic silencing of DNA mutations in advanced cancers, which has important implications for resistance to targeted therapeutics. In a study of 45 patients with cancer, 86 pathogenic DNA alterations were identified, including 17 (19.8%) alterations that were not observed at the RNA level. Among these patients, 31% (14/45) had 1 or more DNA alterations that were not expressed at the RNA level. Examples of genes that had pathogenic DNA alterations not seen at the RNA level included ALK, KDR, and GNAS. On the other hand, alterations involving other genes, including TP53, PIK3CA, and FGFR3, showed 100% concordance between DNA and RNA. This study concluded that a significant number of patients had DNA alterations that are silenced at the RNA level and that transcriptomic silencing merits additional investigation as a mechanism of therapeutic resistance.

Interrogation of gene expression levels

Gene amplification has frequently been described as a mechanism leading to carcinogenesis. Even though gene amplification would be expected to correlate with overexpression, there are cases where these phenomena are not associated. In order to characterize a gene amplification as a “driver” alteration, overexpression is required. Gene expression profiling alone or in combination with copy-number variation (CNV) analysis is used to identify candidate driver genes for molecular therapeutic targeting. In one study, investigators analyzed gene CNV and mRNA expression data from The Cancer Genome Atlas project. They
identified 42 candidate cancer driver genes and validated their oncogenic activity via siRNA knockdown.\textsuperscript{143} In another study, transcriptome and CNV analysis enabled the identification of targetable molecular alterations as well as prognostic and diagnostic biomarkers.\textsuperscript{34} Importantly, some studies suggest that the variability in normal transcript levels between tissues and between individuals means that cancer transcript expression levels must be compared to their normal-tissue counterparts for accuracy.\textsuperscript{7}

Novel bioinformatic approaches in large datasets are essential for exploring and describing the association of gene amplification and expression with mechanisms of carcinogenesis. Launched by the National Institutes of Health in 2010, the Genotype-Tissue Expression (GTEx) Program aims to explore the association between genetic variants and gene expression\textsuperscript{145} and consists of a tissue bank with multiple tissue samples for each donor along with whole-genome and RNA-seq data from approximately 960 deceased adult donors. This Program provides publicly available data to the research community, which investigators can use in studies of mechanisms of gene regulation, genetic variation and its association with gene expression and disease risk, and novel methods of gene expression analysis.\textsuperscript{145,146}

\textit{Machine learning}

Machine learning, a subfield of artificial intelligence, has been playing an increasingly central role in biomedical and pharmaceutical sciences,\textsuperscript{147} primarily owing to the need to develop new tools to analyze the influx of
complex, heterogeneous, and multidimensional biological datasets. Machine learning approaches can be used to detect key genomic and epigenetic features that can help classify patients who may have different responses to a drug. For this purpose, multiple feature-selection algorithms have been proposed, including filters (e.g., Markov blanket filtering), wrappers (e.g., gradient-based-leave-one-out gene selection), and embedded techniques (e.g., block diagonal linear discriminant analysis). Next, a variety of established machine learning algorithms, including artificial neural networks, support vector machines, and decision trees, can build predictive drug response models based on the features. As an example, a multilayer perceptron neural network can be trained to generate an output (e.g., whether the patient responds to targeted treatments) in response to a set of input variables (e.g., genetic variations). Most recent developments focus on deep learning methods, a subset of machine learning based on artificial neural networks. Currently, deep learning approaches hold significant promise as they are capable of unsupervised learning using data that are unstructured or unlabeled, potentially addressing some of the inherent limitations of machine learning.

Transcriptomics in clinical trials

The WINTHER trial was one of the first studies to incorporate transcriptional analysis, in addition to genomics, in order to match patients with solid tumors to therapeutic agents (Table 1). WINTHER was an
international clinical trial directed by the Worldwide Innovative Network for Personalized Cancer Medicine (WIN Consortium) and involved centers in 5 countries. The rationale for the trial was the need to expand the identification of predictive biomarkers beyond genomic aberrations. Therefore, a double biopsy of tumor (primary or metastatic) and normal tissue from each patient was performed after study enrollment. Tissue was used for DNA analysis by NGS of 236 cancer-related genes. In addition, the study included gene expression analysis of matched tumor and normal tissue pairs. Transcriptional data were evaluated for treatment selection if genomic data generated no recommended treatment option. The selection of targeted therapy using transcriptomic analysis occurred in a stepwise process as follows: gene expression analysis was performed on tumor tissue and paired normal samples from individual patients. Bioinformatic analysis was performed, and the differential expression of these genes in tumor versus analogous normal tissue was used to select treatment. Details for each overexpressed or under-expressed mRNA were provided, including gene fold changes, expression intensity, and type of molecular abnormality. Each alteration was evaluated as a potential match with a targeted agent on the basis of a knowledge database. The WINTHER database included information on the gene expression “targeting” and efficacy of both registered drugs and drugs evaluated in clinical trials. Treatment selection was based on the recommendations of a clinical management committee. Finally, the trial evaluated the use of an exploratory matching score. The score, which was
calculated in a *post hoc*, blinded fashion, was derived by dividing the number of molecular alterations that could be associated with a therapeutic agent by the total number of alterations (for DNA analysis) or by adding the reciprocal of the ranks of each matched drug received by the patient according to the WINther algorithm (for RNA analysis).

Of 303 patients who consented, 107 (35%) patients received 1 or more agents and were evaluable for analysis. Patients were heavily pretreated with a median of 3 prior therapies. Among the 107 evaluable patients, 15% had stable disease for 6 months or longer, and 11% had partial or complete responses. Having 2 or fewer previous therapies, an Eastern Cooperative Oncology Group (ECOG) performance status of 0, and a higher matching score were independently associated with longer progression-free survival. ECOG performance status of 0 and a higher matching score were also associated with longer overall survival on multivariate analysis. The WINther trial demonstrated that transcriptomic analysis can be an indispensable tool for the navigation of treatment in selected patients. However, the analysis was complex and required bioinformatic expertise.

Other clinical trials focusing on pediatric patients have matched therapies to molecular alterations identified by transcriptomic analysis.\textsuperscript{32-34} In 1 study, gene expression profiling was performed in 20 patients with refractory pediatric sarcoma to identify overexpressed genes and deregulated pathways that could be therapeutically targeted.\textsuperscript{32} The actionable targets most commonly identified were TOP2A and FGFR1.
upregulation. Nine of the 20 patients received a targeted therapy. Patients who received targeted treatments had higher overall \( P = 0.0014 \) and progression-free \( P = 0.0011 \) survival rates compared to patients who did not.

The Individualized Therapy for Relapsed Malignancies in Childhood (INFORM) study used RNA sequencing in addition to whole-exome and low-coverage whole-genome sequencing in prospectively recruited children with high-risk relapsed or refractory malignancies. An expert multidisciplinary panel prioritized the identified molecular alterations using a customized prioritization algorithm. The algorithm used a 7-step priority scale, ranging from “very low” to “very high,” based on the biological relevance, type of alteration, and potential druggability. Investigators created an internal database comprising genes considered to be potential therapeutic targets. Treatment was selected on the basis of physician choice. In the initial report of 52 patients, candidate targetable molecular alterations were identified in 26 (50%) of the patients, 10 of whom received the respective treatment. Even though patients were heavily pretreated, clinical responses were noted.

The investigators recently reported updated results of the INFORM study. Of 1,300 patients who were enrolled at 72 centers, 525 were included in the analysis. A “very high-” or “high-” priority actionable target was identified in 8% and 14.8% of patients, respectively. Patients who received targeted treatment had longer progression-free survival compared to patients who received non-targeted therapy (204.5 vs. 114 days, \( P = \))
0.0095), although no difference was noted in overall survival between the 2 groups. Patients who received treatment matched to a “very high-” priority target had higher time-to-progression ratios (time to progression before/time to progression after enrollment in INFORM) compared to the remaining patients.

The clinical utility of molecular analysis in pediatric tumors was also demonstrated in the Precision in Pediatric Sequencing (PIPseq) Program study. In this study, whole-exome and RNA sequencing were performed in 101 patients with solid and hematologic malignancies. Molecular alterations (variant calls, copy number variations [CNV], fusions, and overexpressed genes) were initially reviewed by a multidisciplinary molecular tumor board comprising molecular pathologists, pediatric oncologists, medical geneticists, bioinformaticians, and cancer biologists. The final report included the following clinically relevant alterations: driver mutations, gain- or loss-of-function molecular alterations in oncogenes and tumor suppressor genes, respectively, and fusions known or expected to be oncogenic drivers. Investigators included “clinically meaningful” molecular alterations, used for diagnosis, prognosis, treatment (as therapeutic targets), refinement of a therapeutic plan, and/or health maintenance interventions. On the basis of the level of evidence for clinical actionability, a tiered report of all clinically relevant alterations was provided to the referring physician for treatment selection. Transcriptomic analysis identified diagnostic, prognostic, and predictive molecular alterations in 37 (57%) of 65 patients. Overall, 15 (23%)
patients received targetable therapeutic agents on the basis of sequencing findings. These studies serve as proof of concept showing that the use of comprehensive gene expression profiling in daily practice is feasible and provides useful diagnostic, prognostic, and predictive data. Targeted therapeutic agents can be matched to molecular alterations, providing clinical responses even in heavily pretreated patients. Finally, future prospective trials validating the clinical utility of this approach are warranted and should also address the cost, time burden, and inconsistent analysis of transcriptomic data. Ongoing clinical trials are exploring the importance of transcriptomics in cancer therapy.

**Challenges and limitations**

The main challenges associated with transcriptomic analyses are related to the handling of tissue samples and the application of advanced computational methodologies. For example, RNA-seq protocols include sample preparation, RNA isolation and selection, and cDNA synthesis and sequencing followed by bioinformatic analysis. Formalin-fixed, paraffin-embedded tissue samples can include RNA that is degraded, fragmented, or contaminated.\(^{152}\) Contamination caused by errors during sample preparation or by inadequate equipment sterilization can lead to the presence of sequence data from a different sample. Additionally, tumor samples can be contaminated by normal cells that infiltrate or surround the tumor. Experimental methods (cell sorting or laser capture micro-
dissection) and bioinformatics algorithms aim to eliminate contamination effects. Novel methods have been developed to address the issue of low levels of RNA in archival tissue. Additionally, methodologic artifacts are often encountered in transcriptome analysis and require careful assessment.

Another challenge involves the application of advanced computational methodologies. High-level bioinformatic infrastructure is required to conduct complex analyses of profiling data. For instance, in the WINTHER trial, RNA analysis required the systematic development of an algorithm by bioinformaticians. Therefore, the implementation of transcriptomic analysis in clinical workflows may be more complicated than that of genomic analysis. In addition, reproducibility issues need to be addressed. RNA profiling can be used to compare tumor tissue with normal tissue from the same organ, such as in the WINTHER trial; however, some investigators believe that peripheral blood or buccal swab samples could also be used for comparison. This difference may introduce variability in the interpretation of the results.

Overall, investigators who used transcriptomics in clinical trials developed diverse and complex algorithms for characterizing the actionability of molecular alterations. Consequently, the use of transcriptomics in clinical practice is arduous and expensive. For instance, in the INFORM study, the average cost per patient for the molecular analysis, including tissue sample shipment, data processing and storage, labor, and general costs, was approximately €7,000. The time from tissue processing to start of analysis ranged from 0 to 112 days. Therefore, transcriptomic
analysis requires significant optimization, validation and cost decrease in order to be optimally implemented in clinical practice. Standardization of bioinformatic analysis through expert consensus would make the use of transcriptomic analysis in routine clinical practice more consistent.

**Conclusions and future perspectives**

Tumor genomic profiling approaches provide average signatures and a snapshot of the tumor state at the time of biopsy but often do not reflect the complete tumor biology, all tumor components, or the intrinsic heterogeneity of individual cell populations. Innovative emerging techniques, including single-cell transcriptome profiling technologies, will improve our understanding of tumor biology in individual patients and will provide a plethora of translational discovery opportunities. However, understanding tumor complexity and heterogeneity, as well as the dynamic expression of the genome, requires the incorporation of several newer methodologies. The future of precision medicine lies in the integration of genomics, transcriptomics, proteomics, and epigenetics in order to fully elucidate tumor immune and -omic profiles, optimize comprehensive tumor molecular profiles, and inform treatment decisions. By focusing on the role of transcriptomics in identifying appropriate targeted therapies, clinical trials can validate and enrich the available data demonstrating that the use of transcriptomics can increase the number of patients treated with matched targeted therapy and lead to favorable outcomes, hence providing the next frontier for precision medicine.
**Competing interests**

Dr. Apostolia-Maria Tsimberidou has the following financial relationships to disclose: Research Funding (Institution): Immatics, Parker Institute for Cancer Immunotherapy, Tempus, OBI Pharma, EMD Serono, Baxalta, ONYX, Bayer, Boston Biomedical, Placon Therapeutics, Karus Therapeutics, and Tvardi Therapeutics. Consulting or Advisory Role: Covance, Genentech and Tempus.

Dr. Elena Fountzilas has the following financial relationships to disclose:

- Travel grants: Merck, Pfizer, and K.A.M Oncology/Hematology;
- Speaker fees: from Roche, Leo;
- stock ownership Deciphera Pharmaceuticals, Inc.

Leonidas Bleris has the following financial relationships to disclose:

- Research funding from US National Science Foundation (NSF) CAREER grant 1351354, NSF 1361355, and a Cecil H. and Ida Green Endowment.

Dr. Razelle Kurzrock has the following financial relationships to disclose:

- Research Funding (Institution): Incyte, Genentech, Merck Serono, Pfizer, Sequenom, Foundation Medicine, Konica Minolta, Grifols, Biologic Dynamics, and Guardant.
- Consulting role: X-Biotech, Loxo, and Actuate Therapeutics.
- Speaker fees: Roche.
- Ownership interest: IDbyDNA and CureMatch, Inc.
- Board member: CureMatch and CureMetrix.

**Funding**

NIH/NCI, award number P30 CA016672

**Acknowledgments**
Editorial support was provided by Amy Ninetto in Scientific Publications, Research Medical Library, The University of Texas MD Anderson Cancer Center.
## Table 1: Examples of precision medicine trials using transcriptome analysis: Design and outcomes

| Year | First/Last authors | Trial name | Trial type | No. of pts consented | Proportion of pts. matched | Biomarker(s) | Outcome | Institute(s) | Comments |
|------|--------------------|------------|------------|-----------------------|---------------------------|--------------|----------|-------------|----------|
| 2019 | Rodon/Kurzrock     | WINTER     | Prospective, navigational | 303 | 35% | NGS, transcriptomics | Higher matching scores correlated with longer PFS ($P = 0.005$) and OS ($P = 0.03$) | 5 countries (Spain, Israel, France, Canada, USA) | First trial on solid tumors to include transcriptomics |
| 2018 | Weidenbusch/Burdach | PROVABES   | Prospective | 20 | 45% | Gene expression profiling | Matched treatment was associated with improved OS ($P = 0.001$) and PFS ($P = 0.0011$) | Germany | Refractory pediatric sarcomas |
| 2016 | Worst/Fleischhack   | INFORM     | Prospective | 57 | 18% | Whole-exome, RNA sequencing | Feasibility of use of comprehensive molecular analysis to guide treatment | 20 centers, Germany | Pediatric solid and hematologic malignancies |
| 2016 | Oberg/Kung         | PIPseq     | Retrospective review of prospectively recruited pts | 101 | 16% | Whole-exome, RNA sequencing | Potentially targetable genomic alterations were identified in 38/101 (38%) pts | Columbia University Medical Center, USA | Pediatric solid and hematologic malignancies |

**Abbreviations:** NGS = next-generation sequencing, PFS = progression-free survival, OS = overall survival, pts = patients
| Implication                                      | Description                                                                 | Examples/References                                      |
|-------------------------------------------------|-----------------------------------------------------------------------------|----------------------------------------------------------|
| Identification of therapeutic targets          | Identify actionable molecular alterations using RNA-seq and navigate to therapy based on the result | WINTER trial<sup>7,32-34</sup>                           |
| Detection of gene fusions                      | Detect a hybrid gene formed from 2 different genes as a result of chromosomal rearrangements | Targeted RNA-seq for fusion gene detection<sup>37-41</sup> |
| Transcript annotation                          | Discover novel transcripts                                                  | Annotating genomes<sup>42,43</sup>                       |
| Regulation by miRNA sequencing                 | Explore the role of miRNA in mRNA regulation                                | miRNA role in mechanisms of tumorigenesis and as prognostic and predictive biomarkers<sup>44-47</sup> |
| Influence of noncoding RNA sequencing          | Explore the role of noncoding RNA molecules in mRNA regulation              | Noncoding RNA molecules as diagnostic, prognostic, and predictive biomarkers<sup>36,48</sup> |
| Use of prognostic gene expression signatures   | Identify gene expression signatures used to assess patient prognosis         | Oncotype DX<sup>49,71</sup> MammaPrint<sup>50,51</sup>    |
| Use of predictive gene expression signatures   | Identify gene expression signatures used to assess the benefit from treatments | Oncotype DX<sup>49,71</sup>                              |
| Identification of tissue of origin for cancer of unknown primary (CUP) | Identify the primary tumor site using gene expression profiling | Transcriptome-based prediction of primary tumor in patients with CUP<sup>52-56,120</sup> |
| Understanding of tumor heterogeneity           | Use gene expression profiling to identify intrinsic cancer subtypes         | Tumor classification into subtypes<sup>57-59</sup>       |
| **Interrogation of biomarkers for immuno-oncology** | Use immune cell profiling to explore mechanisms of immune escape and identify immune cell phenotypes | Transcriptomics in cancer immunotherapy\(^{60-62,157,158}\) |
|---|---|---|
| **Silencing of the transcriptome** | Understand genomic alterations that are silenced at the transcript level | Identification of discrepancies between DNA molecular alterations and RNA expression and effect on therapeutic resistance\(^{142}\) Silencing may also be exploitable for therapeutic purposes |
| **Interrogation of expression levels** | Understand differences between amplified and expressed genes | Gene amplification is not always associated with increased gene expression\(^{64}\) |
References

1. Kato S, Subbiah V, Kurzrock R: Counterpoint: Successes in the Pursuit of Precision Medicine: Biomarkers Take Credit. J Natl Compr Canc Netw 15:863-866, 2017

2. Subbiah V, Kurzrock R: Debunking the Delusion That Precision Oncology Is an Illusion. Oncologist 22:881-882, 2017

3. Sicklick JK, Kato S, Okamura R, et al: Molecular profiling of cancer patients enables personalized combination therapy: the I-PREDICT study. Nat Med 25:744-750, 2019

4. Tsimberidou AM, Iskander NG, Hong DS, et al: Personalized medicine in a phase I clinical trials program: the MD Anderson Cancer Center initiative. Clin Cancer Res 18:6373-83, 2012

5. Wheler JJ, Janku F, Naing A, et al: Cancer Therapy Directed by Comprehensive Genomic Profiling: A Single Center Study. Cancer Res 76:3690-701, 2016

6. Massard C, Michiels S, Ferte C, et al: High-Throughput Genomics and Clinical Outcome in Hard-to-Treat Advanced Cancers: Results of the MOSCATO 01 Trial. Cancer Discov 7:586-595, 2017

7. Rodon J, Soria JC, Berger R, et al: Genomic and transcriptomic profiling expands precision cancer medicine: the WINther trial. Nat Med 25:751-758, 2019

8. Tsimberidou AM, Wen S, Hong DS, et al: Personalized medicine for patients with advanced cancer in the phase I program at MD Anderson: validation and landmark analyses. Clin Cancer Res 20:4827-36, 2014

9. Tsimberidou AM, Hong DS, Ye Y, et al: Initiative for Molecular Profiling and Advanced Cancer Therapy (IMPACT): An MD Anderson Precision Medicine Study. JCO Precis Oncol 2017, 2017

10. Aftimos PG, Antunes De Melo e Oliveira AM, Hilbers F, et al: 1520First report of AURORA, the breast international group (BIG) molecular screening initiative for metastatic breast cancer (MBC) patients (pts). Annals of Oncology 30, 2019

11. Folprecht G, Aust DE, Roth A, et al: Improving access to molecularly defined clinical trials for patients with colorectal cancer: The EORTC SPECTAcolor platform. Journal of Clinical Oncology 33:575-575, 2015

12. Gerber DE, Oxnard GR, Mandrekar SJ, et al: ALCHEMIST: a clinical trial platform to bring genomic discovery and molecularly targeted therapies to early-stage lung cancer. Journal of Clinical Oncology 33:TPS7583-TPS7583, 2015

13. Herbst RS, Gandara DR, Hirsch FR, et al: Lung Master Protocol (Lung-MAP)-A Biomarker-Driven Protocol for Accelerating Development of Therapies for Squamous Cell Lung Cancer: SWOG S1400. Clin Cancer Res 21:1514-24, 2015

14. Jhaveri KL, Makker V, Wang XV, et al: Ado-trastuzumab emtansine (T-DM1) in patients (pts) with HER2 amplified (amp) tumors excluding breast and gastric/gastro-esophageal junction (GEJ)
adenocarcinomas: Results from the National Cancer Institute (NCI) Molecular Analysis for Therapy Choice (MATCH) trial. Journal of Clinical Oncology 36:100-100, 2018

15. Krop IE, Jegede O, Grilley-Olson JE, et al: Results from molecular analysis for therapy choice (MATCH) arm I: Taselisib for PIK3CA-mutated tumors. Journal of Clinical Oncology 36:101-101, 2018

16. Azad N, Overman M, Gray R, et al: Nivolumab in mismatch-repair deficient (MMR-d) cancers: NCI-MATCH Trial (Molecular Analysis for Therapy Choice). Journal for ImmunoTherapy of Cancer 89, 2017

17. Chae YK, Vaklavas C, Cheng HH, et al: Molecular analysis for therapy choice (MATCH) arm W: Phase II study of AZD4547 in patients with tumors with aberrations in the FGFR pathway. Journal of Clinical Oncology 36:2503-2503, 2018

18. Joshi SS, Maron SB, Lomnicki S, et al: Personalized antibodies for gastroesophageal adenocarcinoma (PANGEA): A phase II precision medicine trial (NCT02213289). Journal of Clinical Oncology 36:TPS198-TPS198, 2018

19. Slosberg ED, Kang BP, Peguero J, et al: Signature program: a platform of basket trials. Oncotarget 9:21383-21395, 2018

20. Demetri GD, von Mehren M, Blanke CD, et al: Efficacy and safety of imatinib mesylate in advanced gastrointestinal stromal tumors. N Engl J Med 347:472-80, 2002

21. Chapman PB, Hauschild A, Robert C, et al: Improved survival with vemurafenib in melanoma with BRAF V600E mutation. N Engl J Med 364:2507-16, 2011

22. Swain SM, Baselga J, Kim SB, et al: Pertuzumab, trastuzumab, and docetaxel in HER2-positive metastatic breast cancer. N Engl J Med 372:724-34, 2015

23. Ramalingam SS, Vansteenkiste J, Planchard D, et al: Overall Survival with Osimertinib in Untreated, EGFR-Mutated Advanced NSCLC. The New England journal of medicine 382:41-50, 2020

24. Zehir A, Benayed R, Shah RH, et al: Mutational landscape of metastatic cancer revealed from prospective clinical sequencing of 10,000 patients. Nat Med 23:703-713, 2017

25. Aisner DL, Sholl LM, Berry LD, et al: The Impact of Smoking and TP53 Mutations in Lung Adenocarcinoma Patients with Targetable Mutations-The Lung Cancer Mutation Consortium (LCMC2). Clin Cancer Res 24:1038-1047, 2018

26. Andre F, Bachelot T, Commo F, et al: Comparative genomic hybridisation array and DNA sequencing to direct treatment of metastatic breast cancer: a multicentre, prospective trial (SAFIR01/UNICANCER). Lancet Oncol 15:267-74, 2014

27. Kris MG, Johnson BE, Berry LD, et al: Using multiplexed assays of oncogenic drivers in lung cancers to select targeted drugs. JAMA 311:1998-2006, 2014
28. Schwaederle M, Parker BA, Schwab RB, et al: Precision Oncology: The UC San Diego Moores Cancer Center PREDICT Experience. Mol Cancer Ther 15:743-52, 2016
29. Von Hoff DD, Stephenson JJ, Jr., Rosen P, et al: Pilot study using molecular profiling of patients' tumors to find potential targets and select treatments for their refractory cancers. J Clin Oncol 28:4877-83, 2010
30. Stockley TL, Oza AM, Berman HK, et al: Molecular profiling of advanced solid tumors and patient outcomes with genotype-matched clinical trials: the Princess Margaret IMPACT/COMPACT trial. Genome Med 8:109, 2016
31. Tredan O, Wang Q, Pissaloux D, et al: Molecular screening program to select molecular-based recommended therapies for metastatic cancer patients: analysis from the ProFiLER trial. Ann Oncol 30:757-765, 2019
32. Weidenbusch B, Richter GHS, Kesper MS, et al: Transcriptome based individualized therapy of refractory pediatric sarcomas: feasibility, tolerability and efficacy. Oncotarget 9:20747-20760, 2018
33. Worst BC, van Tilburg CM, Balasubramanian GP, et al: Next-generation personalised medicine for high-risk paediatric cancer patients - The INFORM pilot study. Eur J Cancer 65:91-101, 2016
34. Oberg JA, Glade Bender JL, Sulis ML, et al: Implementation of next generation sequencing into pediatric hematology-oncology practice: moving beyond actionable alterations. Genome Med 8:133, 2016
35. Cieslik M, Chinnaiyan AM: Cancer transcriptome profiling at the juncture of clinical translation. Nat Rev Genet 19:93-109, 2018
36. Tsai C-H, Yao C-Y, Tien F-M, et al: Incorporation of long non-coding RNA expression profile in the 2017 ELN risk classification can improve prognostic prediction of acute myeloid leukemia patients. EBioMedicine 40:240-250, 2019
37. Heyer EE, Deveson IW, Wooi D, et al: Diagnosis of fusion genes using targeted RNA sequencing. Nat Commun 10:1388, 2019
38. Kim P, Jang YE, Lee S: FusionScan: accurate prediction of fusion genes from RNA-Seq data. Genomics Inform 17:e26, 2019
39. Vu TN, Deng W, Trac QT, et al: A fast detection of fusion genes from paired-end RNA-seq data. BMC Genomics 19:786, 2018
40. Winters JL, Davila JL, McDonald AM, et al: Development and Verification of an RNA Sequencing (RNA-Seq) Assay for the Detection of Gene Fusions in Tumors. J Mol Diagn 20:495-511, 2018
41. Maher CA, Kumar-Sinha C, Cao X, et al: Transcriptome sequencing to detect gene fusions in cancer. Nature 458:97-101, 2009
42. Denoeud F, Aury J-M, Da Silva C, et al: Annotating genomes with massive-scale RNA sequencing. Genome Biology 9:R175, 2008
43. Garber M, Grabherr MG, Guttmann M, et al: Computational methods for transcriptome annotation and quantification using RNA-seq. Nature methods 8:469-477, 2011
44. Wang N, Zheng J, Chen Z, et al: Single-cell microRNA-mRNA co-sequencing reveals non-genetic heterogeneity and mechanisms of microRNA regulation. Nat Commun 10:95, 2019
45. Martinez-Gutierrez AD, Catalan OM, Vazquez-Romo R, et al: miRNA profile obtained by next-generation sequencing in metastatic breast cancer patients is able to predict the response to systemic treatments. Int J Mol Med 44:1267-1280, 2019
46. Yu N, Yong S, Kim HK, et al: Identification of tumor suppressor miRNAs by integrative miRNA and mRNA sequencing of matched tumor-normal samples in lung adenocarcinoma. Mol Oncol 13:1356-1368, 2019
47. Szeto CY, Lin CH, Choi SC, et al: Integrated mRNA and microRNA transcriptome sequencing characterizes sequence variants and mRNA-microRNA regulatory network in nasopharyngeal carcinoma model systems. FEBS Open Bio 4:128-40, 2014
48. Xie L, Yao Z, Zhang Y, et al: Deep RNA sequencing reveals the dynamic regulation of miRNA, lncRNAs, and mRNAs in osteosarcoma tumorigenesis and pulmonary metastasis. Cell Death Dis 9:772, 2018
49. Paik S, Shak S, Tang G, et al: A multigene assay to predict recurrence of tamoxifen-treated, node-negative breast cancer. N Engl J Med 351:2817-26, 2004
50. Krop I, Ismaila N, Andre F, et al: Use of Biomarkers to Guide Decisions on Adjuvant Systemic Therapy for Women With Early-Stage Invasive Breast Cancer: American Society of Clinical Oncology Clinical Practice Guideline Focused Update. J Clin Oncol 35:2838-2847, 2017
51. Cardoso F, van't Veer LJ, Bogaerts J, et al: 70-Gene Signature as an Aid to Treatment Decisions in Early-Stage Breast Cancer. N Engl J Med 375:717-29, 2016
52. Bridgewater J, van Laar R, Floore A, et al: Gene expression profiling may improve diagnosis in patients with carcinoma of unknown primary. British Journal of Cancer 98:1425-1430, 2008
53. Loriot Y, Gross-Goupil M, Lesimple T, et al: Identifying the primary site using gene expression profiling in patients with carcinoma of an unknown primary (CUP): a feasibility study from the GEFCAP. Journal of Clinical Oncology 27:e22168-e22168, 2009
54. Tothill RW, Shi F, Paiman L, et al: Development and validation of a gene expression tumour classifier for cancer of unknown primary. Pathology 47:7-12, 2015
55. Wei IH, Shi Y, Jiang H, et al: RNA-Seq accurately identifies cancer biomarker signatures to distinguish tissue of origin. Neoplasia (New York, N.Y.) 16:918-927, 2014
56. Michuda J, Igartua C, Taxter T, et al: Transcriptome-based cancer type prediction for tumors of unknown origin. Journal of Clinical Oncology 37:3081-3081, 2019
57. Perou CM, Sørlie T, Eisen MB, et al: Molecular portraits of human breast tumours. Nature 406:747-752, 2000
58. Patel AP, Tirosh I, Trombetta JJ, et al: Single-cell RNA-seq highlights intratumoral heterogeneity in primary glioblastoma. Science (New York, N.Y.) 344:1396-1401, 2014

59. Li H, Courtois ET, Sengupta D, et al: Reference component analysis of single-cell transcriptomes elucidates cellular heterogeneity in human colorectal tumors. Nature genetics 49:708-718, 2017

60. Parulkar R, Nguyen A, Sanborn JZ, et al: Evidence for selective silencing of MHC-binding neoeptopes to avoid immune surveillance. Journal of Clinical Oncology 37:2591-2591, 2019

61. Azizi E, Carr AJ, Plitas G, et al: Single-Cell Map of Diverse Immune Phenotypes in the Breast Tumor Microenvironment. Cell 174:1293-1308.e36, 2018

62. Savas P, Virassamy B, Ye C, et al: Single-cell profiling of breast cancer T cells reveals a tissue-resident memory subset associated with improved prognosis. Nature medicine 24:986-993, 2018

63. Adashek JJ, Kato S, Parulkar R, et al: Transcriptomic silencing as a potential mechanism of treatment resistance. JCI Insight 5, 2020

64. Santarius T, Shipley J, Brewer D, et al: A census of amplified and overexpressed human cancer genes. Nature reviews. Cancer 10:59-64, 2010

65. Stein WD, Litman T, Fojo T, et al: A Serial Analysis of Gene Expression (SAGE) database analysis of chemosensitivity: comparing solid tumors with cell lines and comparing solid tumors from different tissue origins. Cancer Res 64:2805-16, 2004

66. Bittner M, Meltzer P, Chen Y, et al: Molecular classification of cutaneous malignant melanoma by gene expression profiling. Nature 406:536-40, 2000

67. Ramaswamy S, Ross KN, Lander ES, et al: A molecular signature of metastasis in primary solid tumors. Nat Genet 33:49-54, 2003

68. Ntzani EE, Ioannidis JP: Predictive ability of DNA microarrays for cancer outcomes and correlates: an empirical assessment. Lancet 362:1439-44, 2003

69. Clough E, Barrett T: The Gene Expression Omnibus Database. Methods in molecular biology (Clifton, N.J.) 1418:93-110, 2016

70. Adetunji MO, Lamont SJ, Schmidt CJ: TransAtlasDB: an integrated database connecting expression data, metadata and variants. Database (Oxford) 2018, 2018

71. Sparano JA, Gray RJ, Makower DF, et al: Adjuvant Chemotherapy Guided by a 21-Gene Expression Assay in Breast Cancer. N Engl J Med 379:111-121, 2018

72. Frith MC, Pheasant M, Mattick JS: The amazing complexity of the human transcriptome. European journal of human genetics : EJHG 13:894-897, 2005

73. Boccaletto P, Machnicka MA, Purta E, et al: MODOMICS: a database of RNA modification pathways. 2017 update. Nucleic Acids Research 46:D303-D307, 2017
74. Alexandrov LB, Nik-Zainal S, Wedge DC, et al: Signatures of mutational processes in human cancer. Nature 500:415-421, 2013
75. Avesson L, Barry G: The emerging role of RNA and DNA editing in cancer. Biochimica et biophysica acta 1845:308-316, 2014
76. Cui Q, Shi H, Ye P, et al: m(6)A RNA Methylation Regulates the Self-Renewal and Tumorigenesis of Glioblastoma Stem Cells. Cell reports 18:2622-2634, 2017
77. Li Z, Weng H, Su R, et al: FTO Plays an Oncogenic Role in Acute Myeloid Leukemia as a N(6)-Methyladenosine RNA Demethylase. Cancer cell 31:127-141, 2017
78. Vareslija D, Priedigkeit N, Fagan A, et al: Transcriptome Characterization of Matched Primary Breast and Brain Metastatic Tumors to Detect Novel Actionable Targets. J Natl Cancer Inst 111:388-398, 2019
79. Smith JL, Ries RE, Hylkema T, et al: Comprehensive Transcriptome Profiling of Cryptic CBFA2T3-GLIS2 Fusion-positive AML Defines Novel Therapeutic Options - A COG and TARGET Pediatric AML Study. Clin Cancer Res, 2019
80. Buffa FM, Camps C, Winchester L, et al: microRNA-associated progression pathways and potential therapeutic targets identified by integrated mRNA and microRNA expression profiling in breast cancer. Cancer research 71:5635-5645, 2011
81. Jacobsen A, Silber J, Harinath G, et al: Analysis of microRNA-target interactions across diverse cancer types. Nature structural & molecular biology 20:1325-1332, 2013
82. Dhawan A, Scott JG, Harris AL, et al: Pan-cancer characterisation of microRNA across cancer hallmarks reveals microRNA-mediated downregulation of tumour suppressors. Nature Communications 9:5228, 2018
83. Czech MP: MicroRNAs as therapeutic targets. The New England journal of medicine 354:1194-1195, 2006
84. Roccaro AM, Sacco A, Thompson B, et al: MicroRNAs 15a and 16 regulate tumor proliferation in multiple myeloma. Blood 113:6669-6680, 2009
85. Hayashita Y, Osada H, Tatematsu Y, et al: A polycistronic microRNA cluster, miR-17-92, is overexpressed in human lung cancers and enhances cell proliferation. Cancer research 65:9628-9632, 2005
86. Korpal M, Lee ES, Hu G, et al: The miR-200 family inhibits epithelial-mesenchymal transition and cancer cell migration by direct targeting of E-cadherin transcriptional repressors ZEB1 and ZEB2. The Journal of biological chemistry 283:14910-14914, 2008
87. He L, He X, Lim LP, et al: A microRNA component of the p53 tumour suppressor network. Nature 447:1130-1134, 2007
88. Lu J, Getz G, Miska EA, et al: MicroRNA expression profiles classify human cancers. Nature 435:834-8, 2005
89. Fountzilas E, Kelly AD, Perez-Atayde AR, et al: A microRNA activity map of human mesenchymal tumors: connections to oncogenic
90. Yanaihara N, Caplen N, Bowman E, et al: Unique microRNA molecular profiles in lung cancer diagnosis and prognosis. Cancer Cell 9:189-98, 2006

91. Foekens JA, Sieuwerts AM, Smid M, et al: Four miRNAs associated with aggressiveness of lymph node-negative, estrogen receptor-positive human breast cancer. Proc Natl Acad Sci U S A 105:13021-6, 2008

92. Lamichhane SR, Thachil T, De Ieso P, et al: Prognostic Role of MicroRNAs in Human Non-Small-Cell Lung Cancer: A Systematic Review and Meta-Analysis. Disease markers 2018:8309015-8309015, 2018

93. Hu S, Yuan Y, Song Z, et al: Expression Profiles of microRNAs in Drug-Resistant Non-Small Cell Lung Cancer Cell Lines Using microRNA Sequencing. Cellular Physiology and Biochemistry 51:2509-2522, 2018

94. Ma T, Yang L, Zhang J: MiRNA-542-3p downregulation promotes trastuzumab resistance in breast cancer cells via AKT activation. Oncology reports 33:1215-1220, 2015

95. Wagenseller AG, Shada A, D'Auria KM, et al: MicroRNAs induced in melanoma treated with combination targeted therapy of Temsirolimus and Bevacizumab. Journal of translational medicine 11:218-218, 2013

96. Hannafon BN, Ding W-Q: Intercellular communication by exosome-derived microRNAs in cancer. International journal of molecular sciences 14:14240-14269, 2013

97. Tran N: Cancer Exosomes as miRNA Factories. Trends in cancer 2:329-331, 2016

98. Anfossi S, Babayan A, Pantel K, et al: Clinical utility of circulating non-coding RNAs - an update. Nature reviews. Clinical oncology 15:541-563, 2018

99. Mercer TR, Dinger ME, Mattick JS: Long non-coding RNAs: insights into functions. Nature reviews. Genetics 10:155-159, 2009

100. Cabili MN, Trapnell C, Goff L, et al: Integrative annotation of human large intergenic noncoding RNAs reveals global properties and specific subclasses. Genes & development 25:1915-1927, 2011

101. Liu L, Meng T, Yang X-H, et al: Prognostic and predictive value of long non-coding RNA GAS5 and mircoRNA-221 in colorectal cancer and their effects on colorectal cancer cell proliferation, migration and invasion. Cancer biomarkers : section A of Disease markers 22:283-299, 2018

102. Yuan T, Huang X, Woodcock M, et al: Plasma extracellular RNA profiles in healthy and cancer patients. Scientific reports 6:19413-19413, 2016

103. Zhang R, Xia Y, Wang Z, et al: Serum long non coding RNA MALAT-1 protected by exosomes is up-regulated and promotes cell proliferation and migration in non-small cell lung cancer. Biochemical and biophysical research communications 490:406-414, 2017
104. Nilsson J, Skog J, Nordstrand A, et al: Prostate cancer-derived urine exosomes: a novel approach to biomarkers for prostate cancer. British journal of cancer 100:1603-1607, 2009
105. Xiao Y, Yurievich UA, Yosypovych SV: Long noncoding RNA XIST is a prognostic factor in colorectal cancer and inhibits 5-fluorouracil-induced cell cytotoxicity through promoting thymidylate synthase expression. Oncotarget 8:83171-83182, 2017
106. Li L, Shang J, Zhang Y, et al: MEG3 is a prognostic factor for CRC and promotes chemosensitivity by enhancing oxaliplatin-induced cell apoptosis. Oncology reports 38:1383-1392, 2017
107. Godinho MFE, Sieuwerts AM, Look MP, et al: Relevance of BCAR4 in tamoxifen resistance and tumour aggressiveness of human breast cancer. British Journal of Cancer 103:1284-1291, 2010
108. Shi S-J, Wang L-J, Yu B, et al: LncRNA-ATB promotes trastuzumab resistance and invasion-metastasis cascade in breast cancer. Oncotarget 6:11652-11663, 2015
109. Tang H, Wang S, Xiao G, et al: Comprehensive evaluation of published gene expression prognostic signatures for biomarker-based lung cancer clinical studies. Annals of oncology : official journal of the European Society for Medical Oncology 28:733-740, 2017
110. Liu MC, Pitcher BN, Mardis ER, et al: PAM50 gene signatures and breast cancer prognosis with adjuvant anthracycline- and taxane-based chemotherapy: correlative analysis of C9741 (Alliance). NPJ breast cancer 2:15023, 2016
111. Maak M, Simon I, Nitsche U, et al: Independent validation of a prognostic genomic signature (ColoPrint) for patients with stage II colon cancer. Annals of surgery 257:1053-1058, 2013
112. Srivastava G, Renfro LA, Behrens RJ, et al: Prospective multicenter study of the impact of oncotype DX colon cancer assay results on treatment recommendations in stage II colon cancer patients. The oncologist 19:492-497, 2014
113. Schwartz GW, Petrovic J, Zhou Y, et al: Differential Integration of Transcriptome and Proteome Identifies Pan-Cancer Prognostic Biomarkers. Front Genet 9:205, 2018
114. Smyth EC, Nyamundanda G, Cunningham D, et al: A seven-Gene Signature assay improves prognostic risk stratification of perioperative chemotherapy treated gastroesophageal cancer patients from the MAGIC trial. Annals of oncology : official journal of the European Society for Medical Oncology 29:2356-2362, 2018
115. Wang B, Wan F, Sheng H, et al: Identification and validation of an 18-gene signature highly-predictive of bladder cancer metastasis. Scientific Reports 8:374, 2018
116. Fountzilas E, Markou K, Vlachtsis K, et al: Identification and validation of gene expression models that predict clinical outcome in patients with early-stage laryngeal cancer. Annals of oncology : official journal of the European Society for Medical Oncology 23:2146-2153, 2012
117. Konstantinopoulos PA, Cannistra SA, Fountzilas H, et al: Integrated analysis of multiple microarray datasets identifies a reproducible survival predictor in ovarian cancer. PloS one 6:e18202-e18202, 2011

118. Bertucci F, Ueno NT, Finetti P, et al: Gene expression profiles of inflammatory breast cancer: correlation with response to neoadjuvant chemotherapy and metastasis-free survival. Annals of oncology : official journal of the European Society for Medical Oncology 25:358-365, 2014

119. Cao B, Luo L, Feng L, et al: A network-based predictive gene-expression signature for adjuvant chemotherapy benefit in stage II colorectal cancer. BMC cancer 17:844-844, 2017

120. Xu Q, Chen J, Ni S, et al: Pan-cancer transcriptome analysis reveals a gene expression signature for the identification of tumor tissue origin. Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc 29:546-556, 2016

121. Hayashi H, Kurata T, Takiguchi Y, et al: Randomized Phase II Trial Comparing Site-Specific Treatment Based on Gene Expression Profiling With Carboplatin and Paclitaxel for Patients With Cancer of Unknown Primary Site. Journal of clinical oncology : official journal of the American Society of Clinical Oncology 37:570-579, 2019

122. Fizazi K, Maillard A, Penel N, et al: A phase 3 trial of empiric chemotherapy with cisplatin and gemcitabine or systemic treatment tailored by molecular gene expression analysis in patients with carcinomas of an unknown primary (CUP) site (GEFCAPI 04), ESMO 2019 Congress, Annals of Oncology, 2019, pp v851-v934

123. Gerlinger M, Rowan AJ, Horswell S, et al: Intratumor heterogeneity and branched evolution revealed by multiregion sequencing. The New England journal of medicine 366:883-892, 2012

124. Norton N, Advani PP, Serie DJ, et al: Assessment of Tumor Heterogeneity, as Evidenced by Gene Expression Profiles, Pathway Activation, and Gene Copy Number, in Patients with Multifocal Invasive Lobular Breast Tumors. PloS one 11:e0153411-e0153411, 2016

125. Fan J, Lee H-O, Lee S, et al: Linking transcriptional and genetic tumor heterogeneity through allele analysis of single-cell RNA-seq data. Genome research 28:1217-1227, 2018

126. Hong SP, Chan TE, Lombardo Y, et al: Single-cell transcriptomics reveals multi-step adaptations to endocrine therapy. Nature Communications 10:3840, 2019

127. Levitin HM, Yuan J, Sims PA: Single-Cell Transcriptomic Analysis of Tumor Heterogeneity. Trends in cancer 4:264-268, 2018

128. Goodman AM, Piccioni D, Kato S, et al: Prevalence of PDL1 Amplification and Preliminary Response to Immune Checkpoint Blockade in Solid Tumors. JAMA oncology 4:1237-1244, 2018

129. Le DT, Uram JN, Wang H, et al: PD-1 Blockade in Tumors with Mismatch-Repair Deficiency. The New England journal of medicine 372:2509-2520, 2015
130. Goodman AM, Kato S, Bazhenova L, et al: Tumor Mutational Burden as an Independent Predictor of Response to Immunotherapy in Diverse Cancers. Molecular cancer therapeutics 16:2598-2608, 2017
131. Goodman AM, Sokol ES, Frampton GM, et al: Microsatellite-Stable Tumors with High Mutational Burden Benefit from Immunotherapy. Cancer immunology research 7:1570-1573, 2019
132. Zaretsky JM, Garcia-Diaz A, Shin DS, et al: Mutations Associated with Acquired Resistance to PD-1 Blockade in Melanoma. The New England journal of medicine 375:819-829, 2016
133. Hugo W, Zaretsky JM, Sun L, et al: Genomic and Transcriptomic Features of Response to Anti-PD-1 Therapy in Metastatic Melanoma. Cell 165:35-44, 2016
134. Peng W, Chen JQ, Liu C, et al: Loss of PTEN Promotes Resistance to T Cell-Mediated Immunotherapy. Cancer discovery 6:202-216, 2016
135. Danaher P, Warren S, Dennis L, et al: Gene expression markers of Tumor Infiltrating Leukocytes. Journal for immunotherapy of cancer 5:18-18, 2017
136. Lee W-C, Diao L, Wang J, et al: Multiregion gene expression profiling reveals heterogeneity in molecular subtypes and immunotherapy response signatures in lung cancer. Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc 31:947-955, 2018
137. Riaz N, Havel JJ, Makarov V, et al: Tumor and Microenvironment Evolution during Immunotherapy with Nivolumab. Cell 171:934-949.e16, 2017
138. Mandal R, Şenbabaoğlu Y, Desrichard A, et al: The head and neck cancer immune landscape and its immunotherapeutic implications. JCI insight 1:e89829-e89829, 2016
139. Groenenboom MAC, Marée AFM, Hogeweg P: The RNA silencing pathway: the bits and pieces that matter. PLoS computational biology 1:155-165, 2005
140. Vainio P, Mpindi J-P, Kohonen P, et al: High-throughput transcriptomic and RNAi analysis identifies AIM1, ERGIC1, TMED3 and TPX2 as potential drug targets in prostate cancer. PloS one 7:e39801-e39801, 2012
141. Golan T, Khvalevsky EZ, Hubert A, et al: RNAi therapy targeting KRAS in combination with chemotherapy for locally advanced pancreatic cancer patients. Oncotarget 6:24560-24570, 2015
142. Adashek JJ, Kato S, Parulkar R, et al: RNAseq in addition to next generation sequencing in advanced genitourinary cancers reveals transcriptomic silencing of DNA mutations: Implications for resistance to targeted therapeutics. Journal of Clinical Oncology 37:583-583, 2019
143. Chen Y, McGee J, Chen X, et al: Identification of druggable cancer driver genes amplified across TCGA datasets. PloS one 9:e98293-e98293, 2014
144. Caburet S, Anttonen M, Todeschini A-L, et al: Combined comparative genomic hybridization and transcriptomic analyses of ovarian
granulosa cell tumors point to novel candidate driver genes. BMC cancer 15:251-251, 2015
145. Consortium GT, Laboratory DA, Coordinating Center —Analysis Working G, et al: Genetic effects on gene expression across human tissues. Nature 550:204-213, 2017
146. Li X, Kim Y, Tsang EK, et al: The impact of rare variation on gene expression across tissues. Nature 550:239-243, 2017
147. Kourou K, Exarchos TP, Exarchos KP, et al: Machine learning applications in cancer prognosis and prediction. Computational and structural biotechnology journal 13:8-17, 2014
148. Levine AB, Schlosser C, Grewal J, et al: Rise of the Machines: Advances in Deep Learning for Cancer Diagnosis. Trends in cancer 5:157-169, 2019
149. Adamson AS, Welch HG: Machine Learning and the Cancer-Diagnosis Problem - No Gold Standard. The New England journal of medicine 381:2285-2287, 2019
150. van Tilburg CM, Pfaff E, Pajtler KW, et al: The pediatric precision oncology study INFORM: Clinical outcome and benefit for molecular subgroups. Journal of Clinical Oncology 38:LBA10503-LBA10503, 2020
151. Wagle N, Berger MF, Davis MJ, et al: High-throughput detection of actionable genomic alterations in clinical tumor samples by targeted, massively parallel sequencing. Cancer discovery 2:82-93, 2012
152. Sinicropi D, Qu K, Collin F, et al: Whole transcriptome RNA-Seq analysis of breast cancer recurrence risk using formalin-fixed paraffin-embedded tumor tissue. PLoS One 7:e40092, 2012
153. Nieuwenhuis TO, Yang SY, Verma RX, et al: Consistent RNA sequencing contamination in GTEx and other data sets. Nature Communications 11:1933, 2020
154. Ong C-AJ, Tan QX, Lim HJ, et al: An Optimised Protocol Harnessing Laser Capture Microdissection for Transcriptomic Analysis on Matched Primary and Metastatic Colorectal Tumours. Scientific Reports 10:682, 2020
155. Shen Q, Hu J, Jiang N, et al: contamDE: differential expression analysis of RNA-seq data for contaminated tumor samples. Bioinformatics 32:705-712, 2015
156. Ramalingam N, Lee Y, Szpanskowski L, et al: Abstract LB-326: Full-Length mRNA transcriptome analysis of matched circulating tumor and immune cells from breast cancer subjects. Cancer Research 79:LB-326-LB-326, 2019
157. Chung W, Eum HH, Lee H-O, et al: Single-cell RNA-seq enables comprehensive tumour and immune cell profiling in primary breast cancer. Nature communications 8:15081-15081, 2017
158. Li B, Cui Y, Diehn M, et al: Development and Validation of an Individualized Immune Prognostic Signature in Early-Stage Nonsquamous Non-Small Cell Lung Cancer. JAMA oncology 3:1529-1537, 2017
Figure legend

Figure 1. Noncoding RNAs. The role of noncoding RNAs in cancer diagnosis, prognosis, prediction of response to cancer therapy and disease monitoring is currently under investigation. MicroRNAs (miRNAs) are noncoding RNAs that play an important role as regulators of gene expression. A primary miRNA transcript is cleaved by the microprocessor complex Drosha-DGCR8 in the nucleus. The resulting pre-miRNA is exported from the nucleus. In the cytoplasm, Dicer cleaves the pre-miRNA hairpin to its mature length. The mature miRNA is loaded into the RNA-induced silencing complex (RISC), where it guides RISC to silence target mRNA through mRNA degradation or translational repression.